Sale!

DNAAF3 Gene Primary Ciliary Dyskinesia Type 2 Genetic Test Cost

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The DNAAF3 Gene Primary Ciliary Dyskinesia Type 2 Genetic Test is a specialized diagnostic tool available at DNA Labs UAE, designed to identify mutations in the DNAAF3 gene, which are associated with Primary Ciliary Dyskinesia (PCD) Type 2. PCD is a rare genetic disorder characterized by chronic respiratory tract infections, abnormal organ positioning, and infertility due to defects in the structure and function of cilia, which are microscopic, hair-like structures that line the respiratory tract, middle ear, and other organs.

The DNAAF3 gene plays a crucial role in the development and function of cilia. Mutations in this gene can lead to the improper formation or function of cilia, resulting in the symptoms associated with PCD. By analyzing the DNAAF3 gene, this test can confirm a diagnosis of PCD Type 2, allowing for a better understanding of the condition and enabling targeted management and treatment strategies.

The test is conducted at DNA Labs UAE, a facility known for its advanced genetic testing capabilities. The cost of the DNAAF3 Gene Primary Ciliary Dyskinesia Type 2 Genetic Test is 4400 AED. This test is a valuable resource for individuals exhibiting symptoms of PCD or those with a family history of the condition, providing crucial information for managing their health.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

DNAAF3 Gene Primary Ciliary Dyskinesia Type 2 Genetic Test

At DNA Labs UAE, we offer the DNAAF3 Gene Primary Ciliary Dyskinesia Type 2 Genetic Test to help diagnose and understand this genetic disorder. This test is specifically designed to analyze the DNAAF3 gene, which is associated with primary ciliary dyskinesia type 2.

Test Components

  • Test Name: DNAAF3 Gene Primary Ciliary Dyskinesia Type 2 Genetic Test
  • Price: 4400.0 AED
  • Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
  • Report Delivery: 3 to 4 Weeks
  • Method: NGS Technology
  • Test Type: Ear Nose Throat Disorders
  • Doctor: ENT Doctor
  • Test Department: Genetics

Pre Test Information

Before undergoing the DNAAF3 Gene Primary Ciliary Dyskinesia Type 2 Genetic Test, it is important to provide the clinical history of the patient who is going for the test. Additionally, a genetic counseling session may be conducted to draw a pedigree chart of family members affected with SLC52A3 Gene Brown-Vialetto-Van Laere syndrome 1 NGS Genetic DNA Test gene SLC52A19.

Test Details

The DNAAF3 gene is associated with primary ciliary dyskinesia type 2, a genetic disorder that affects the functioning of cilia in the respiratory tract. This can lead to chronic respiratory infections and other related symptoms. Our NGS (Next-Generation Sequencing) genetic testing method allows us to analyze the DNA sequence of an individual’s genes. In the context of primary ciliary dyskinesia, this test can identify any mutations or variations in the DNAAF3 gene that may be responsible for the disorder. This information is valuable for diagnosis, genetic counseling, and potential treatment options.

Test Name DNAAF3 Gene Primary ciliary dyskinesia type 2 Genetic Test
Components
Price 4400.0 AED
Sample Condition Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery 3 to 4 Weeks
Method NGS Technology
Test type Ear Nose Throat Disorders
Doctor ENT Doctor
Test Department: Genetics
Pre Test Information Clinical History of Patient who is going for SLC52A3 Gene Brown-Vialetto-Van Laere syndrome 1 NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with SLC52A3 Gene Brown-Vialetto-Van Laere syndrome 1 NGS Genetic DNA Test gene SLC52A19
Test Details

The DNAAF3 gene is associated with primary ciliary dyskinesia type 2, a genetic disorder that affects the functioning of cilia in the respiratory tract, causing chronic respiratory infections and other related symptoms. NGS (Next-Generation Sequencing) genetic testing is a method used to analyze the DNA sequence of an individual’s genes. In the context of primary ciliary dyskinesia, NGS genetic testing can be used to identify any mutations or variations in the DNAAF3 gene that may be responsible for the disorder. This information can help with diagnosis, genetic counseling, and potentially guide treatment options.